Literature DB >> 16523260

Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization.

Katharina Glatz-Krieger1, Mona Pache, Coya Tapia, Alain Fuchs, Spasenija Savic, Dieter Glatz, Michael Mihatsch, Peter Meyer.   

Abstract

To assess the differences between melanomas of different location and different etiology, 372 malignant melanomas were brought in a tissue microarray format. The collection included 23 acral and 118 non-acral skin melanomas, 9 mucosal melanomas, 100 uveal melanomas, and 122 melanoma metastases. Fluorescence in situ hybridization (FISH) was used to assess copy number changes of the cyclin D1 (CCND1), MDM2, c-myc (MYC), and HER2 genes. FISH analysis revealed distinct differences between melanomas from different locations. CCND1 amplifications were detected in skin melanomas from sites with chronic sun exposure (6 of 32 cases), acral melanomas (4 of 17 cases), and mucosal melanomas (one of ten cases) but not in uveal melanomas. High-level MDM2 amplifications were exclusively present in acral melanomas (2 of 19 cases). MYC copy number gains were detected in 32 of 71 uveal melanomas, five of eight mucosal melanomas, and 6 of 67 melanomas from sites with intermittent sun exposure but not in acral melanomas nor melanomas from sites with chronic sun exposure. Alterations of the MYC gene were associated with advanced tumor stage. There were no high-level HER2 amplifications. Site-specific genetic and epigenetic features may impact the response of melanomas to various anti-cancer drugs and should be considered in future studies on the molecular pathogenesis of malignant melanomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16523260     DOI: 10.1007/s00428-006-0167-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  42 in total

1.  Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis.

Authors:  K Sisley; I G Rennie; M A Parsons; R Jacques; D W Hammond; S M Bell; A M Potter; R C Rees
Journal:  Genes Chromosomes Cancer       Date:  1997-05       Impact factor: 5.006

2.  Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.

Authors:  B Bodey; B Bodey; A M Gröger; J V Luck; S E Siegel; C R Taylor; H E Kaiser
Journal:  Anticancer Res       Date:  1997 Mar-Apr       Impact factor: 2.480

3.  Tissue microarrays.

Authors:  Ronald Simon; Martina Mirlacher; Guido Sauter
Journal:  Methods Mol Med       Date:  2004

4.  Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization.

Authors:  B C Bastian; P E LeBoit; H Hamm; E B Bröcker; D Pinkel
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

5.  Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma.

Authors:  D L Persons; D A Arber; J A Sosman; K A Borelli; M L Slovak
Journal:  Anticancer Res       Date:  2000 May-Jun       Impact factor: 2.480

6.  Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.

Authors:  Fabio Pastorino; Chiara Brignole; Danilo Marimpietri; Gabriella Pagnan; Adriana Morando; Domenico Ribatti; Sean C Semple; Claudio Gambini; Theresa M Allen; Mirco Ponzoni
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

7.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Authors:  M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

8.  Non-random abnormalities of chromosomes 3, 6, and 8 associated with posterior uveal melanoma.

Authors:  K Sisley; D W Cottam; I G Rennie; M A Parsons; A M Potter; C W Potter; R C Rees
Journal:  Genes Chromosomes Cancer       Date:  1992-10       Impact factor: 5.006

9.  Distinct chromosomal aberrations in sinonasal mucosal melanoma as detected by comparative genomic hybridization.

Authors:  Marcory van Dijk; Sandra Sprenger; Paul Rombout; Henri Marres; Johannes Kaanders; Judith Jeuken; Dirk Ruiter
Journal:  Genes Chromosomes Cancer       Date:  2003-02       Impact factor: 5.006

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  12 in total

1.  Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma.

Authors:  Denitsa Koynova; Ekaterina Jordanova; Nicole Kukutsch; Pieter van der Velden; Draga Toncheva; Nelleke Gruis
Journal:  J Cancer Res Clin Oncol       Date:  2006-09-15       Impact factor: 4.553

2.  Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.

Authors:  Diane Tseng; Julie Kim; Andrea Warrick; Dylan Nelson; Marina Pukay; Carol Beadling; Michael Heinrich; Maria Angelica Selim; Christopher L Corless; Kelly Nelson
Journal:  J Am Acad Dermatol       Date:  2014-05-17       Impact factor: 11.527

Review 3.  Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features.

Authors:  Emily A Merkel; Pedram Gerami
Journal:  Lab Invest       Date:  2017-01-16       Impact factor: 5.662

Review 4.  Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place?

Authors:  Ahmed Lasfar; Karine A Cohen-Solal
Journal:  Carcinogenesis       Date:  2010-07-23       Impact factor: 4.944

5.  Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.

Authors:  Stephan W Jahn; Karl Kashofer; Iris Halbwedl; Gerlinde Winter; Laila El-Shabrawi-Caelen; Thomas Mentzel; Gerald Hoefler; Bernadette Liegl-Atzwanger
Journal:  Mod Pathol       Date:  2015-03-13       Impact factor: 7.842

Review 6.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.

Authors:  Boris C Bastian
Journal:  Annu Rev Pathol       Date:  2014       Impact factor: 23.472

7.  [Molecular heterogeneity of malignant melanomas].

Authors:  K Glatz
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

8.  Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.

Authors:  Joan A Puig-Butillé; Celia Badenas; Zighereda Ogbah; Cristina Carrera; Paula Aguilera; Josep Malvehy; Susana Puig
Journal:  Exp Dermatol       Date:  2013-02       Impact factor: 3.960

9.  Oncogenic mutations in GNAQ occur early in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Long; Shenghui Duan; M Laurin Council; Anne M Bowcock; J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-21       Impact factor: 4.799

10.  [Uncommon variants of malignant melanocytic neoplasms].

Authors:  T Mentzel
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.